杭州启明医疗器械股份有限公司（香港联交所股份代号：02500）于2026年1月6日发布2025年12月股份变动月报表。公告显示，截至2025年12月31日，公司已发行H股441,010,235股及非上市外资股1,208股，总计441,011,443股；该期间内，无新增股份发行、购回或注销事项，股本结构维持稳定。
根据公告，公司于报告期内已发行股份（不含库存股份）保持在441,010,235股（H股）及1,208股（非上市外资股），均与上月底持平。公司亦披露，曾于2021年购回合计3,114,000股H股，虽尚未注销，但本月无进一步购回或发行活动。公司批准的股份期权计划在报告期内未触发新增发行或库存股变动，目前可供行使的潜在发行上限为44,101,023股。
公告特别说明，公司所有股份交易及信息披露均符合香港联合交易所有限公司的相关上市规则及法律规定。该月报表由执行董事柳美荣签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.